Business Context and Reporting Period
Neuropace, Inc. (NPCE) filed a Form 8-K on November 28, 2023, reporting the entry into a material definitive agreement. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not report standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for a specific reporting period. The primary financial disclosure relates to a new revenue stream from a collaboration agreement.
- Total Anticipated Revenue: Approximately $3.7 million from the collaboration.
- Payment Structure: Includes a trial initiation payment (anticipated Q4 2023) and recurring quarterly payments.
Material Changes
The material change reported is the execution of a collaboration agreement with Rapport Therapeutics, Inc. on November 28, 2023. Under this agreement, NeuroPace will provide site data and utilize its RNS System monitoring and data analytics capabilities to support Rapport's Phase 2a trial of their GAMA 8 Receptor-Associated Protein (RAP) compound.
Outlook, Risks, and Unusual Items
Agreement Terms: The collaboration spans four phases over nine quarters (Q4 2023 to Q4 2025). Payments are tied to milestones and deliverables.
Termination: The agreement is subject to early termination under specified circumstances, including "for cause" as defined in the contract.
Extension: The term may be extended upon mutual agreement of the parties.
Risks: The filing does not explicitly detail financial risks beyond the contingent nature of milestone payments and the possibility of early termination.
Investor Verification Checklist
- Verify the timing and receipt of the anticipated trial initiation payment in Q4 2023.
- Monitor the achievement of specific milestones required to trigger recurring quarterly payments.
- Assess the progress of Rapport Therapeutics' Phase 2a trial, as NeuroPace's revenue is contingent on patient enrollment and trial efficacy evaluation.
- Review future filings for any amendments or early termination notices regarding the agreement.